NVIV - InVivo Therapeutics Holdings Corp.

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue---
Cost of Revenue---
Gross Profit---
Operating Expenses
Research Development12,55710,05810,273
Selling General and Administrative11,50612,3407,566
Non Recurring---
Total Operating Expenses---
Operating Income or Loss-24,063-22,398-17,839
Income from Continuing Operations
Total Other Income/Expenses Net780-10,744-371
Earnings Before Interest and Taxes-23,283-33,142-18,210
Interest Expense155172136
Income Before Tax-23,438-33,314-18,346
Income Tax Expense---
Minority Interest---
Net Income From Continuing Ops-23,438-33,314-18,346
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income-23,438-33,314-18,346
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares-23,438-33,314-18,346